Voloridge Investment Management’s Sabra Healthcare REIT SBRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-48,368
Closed -$690K 1330
2023
Q4
$690K Buy
+48,368
New +$687K ﹤0.01% 990
2023
Q1
Sell
-11,651
Closed -$145K 1584
2022
Q4
$145K Sell
11,651
-19,509
-63% -$249K ﹤0.01% 1392
2022
Q3
$409K Sell
31,160
-18,854
-38% -$279K ﹤0.01% 1294
2022
Q2
$699K Buy
+50,014
New +$669K ﹤0.01% 1263
2021
Q3
Sell
-327,351
Closed -$5.96M 1840
2021
Q2
$5.96M Buy
327,351
+147,867
+82% +$2.63M 0.04% 576
2021
Q1
$3.12M Buy
179,484
+148,583
+481% +$2.61M 0.02% 662
2020
Q4
$537K Buy
+30,901
New +$493K ﹤0.01% 1110
2020
Q2
Sell
-36,433
Closed -$398K 1467
2020
Q1
$398K Sell
36,433
-57,550
-61% -$1.06M 0.01% 780
2019
Q4
$2.01M Buy
+93,983
New +$2.1M 0.04% 490
2018
Q2
Sell
-221,959
Closed -$3.92M 581
2018
Q1
$3.92M Sell
221,959
-39,190
-15% -$691K 0.09% 192
2017
Q4
$4.9M Buy
+261,149
New +$5.19M 0.11% 203

Other funds holding SBRA

Voloridge Investment Management's SBRA Position: Q1 2024 in Review

Voloridge Investment Management sold out of Sabra Healthcare REIT (SBRA) in Q1 2024, closing a stake of 48,368 shares — an estimated $690K sold.

Voloridge Investment Management first reported a position in SBRA in Q4 2017 and held it in 11 quarters. The position peaked at $5.96M in Q2 2021. 342 funds tracked by Wall St. Rank hold SBRA as of Q1 2024.

  • Voloridge Investment Management reported no remaining Sabra Healthcare REIT position as of Q1 2024 after selling out during the quarter.
  • Voloridge Investment Management sold 48,368 Sabra Healthcare REIT shares in Q1 2024, an estimated $690K.
  • Voloridge Investment Management first reported a position in Sabra Healthcare REIT in Q4 2017 and held it in 11 quarters.
  • Voloridge Investment Management's Sabra Healthcare REIT position peaked at $5.96M in Q2 2021.
  • 342 funds tracked by Wall St. Rank held Sabra Healthcare REIT as of Q1 2024.

Based on Voloridge Investment Management's 13F filing for Q1 2024, filed 15 May 2024.